NO940180L - Anvendelse av IGF-I - Google Patents

Anvendelse av IGF-I

Info

Publication number
NO940180L
NO940180L NO940180A NO940180A NO940180L NO 940180 L NO940180 L NO 940180L NO 940180 A NO940180 A NO 940180A NO 940180 A NO940180 A NO 940180A NO 940180 L NO940180 L NO 940180L
Authority
NO
Norway
Prior art keywords
igf
treatment
type
diabetes mellitus
drug
Prior art date
Application number
NO940180A
Other languages
English (en)
Other versions
NO940180D0 (no
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO940180L publication Critical patent/NO940180L/no
Publication of NO940180D0 publication Critical patent/NO940180D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anvendelse av IGF-I til frem- stilling av et medikament for behand- ling av type l diabetes mellitus. Medikamentet omfatter en subkutan dose som ikke er høyere enn den nødvendige for å oppnå et IGF-I-serumnivå karak- teristisk for friske individer, dvs. en fysiologisk erstatning for serum-IGF-I. Denne behandling vil være spesielt verdifull for behandling av barn eller ungdom med type l diabetes mellitus, og kan føre til forbedringer i deres pubertetsvekst.
NO940180A 1992-05-19 1994-01-18 Anvendelse av IGF-I NO940180D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (2)

Publication Number Publication Date
NO940180L true NO940180L (no) 1994-01-18
NO940180D0 NO940180D0 (no) 1994-01-18

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940180A NO940180D0 (no) 1992-05-19 1994-01-18 Anvendelse av IGF-I

Country Status (11)

Country Link
US (1) US5466670A (no)
EP (1) EP0613376B1 (no)
JP (1) JPH06509361A (no)
AT (1) ATE207758T1 (no)
AU (1) AU669894B2 (no)
CA (1) CA2112358A1 (no)
DE (1) DE69331045T2 (no)
NO (1) NO940180D0 (no)
NZ (1) NZ252359A (no)
SE (1) SE9201573D0 (no)
WO (1) WO1993023071A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2208305T3 (es) 1999-04-08 2004-06-16 Genentech, Inc. Composicion basada en polipeptidos de carga opuesta..
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
RU2165767C1 (ru) * 2000-06-09 2001-04-27 Чернов Юрий Николаевич Антидиабетическое средство
JP2004518647A (ja) 2000-12-15 2004-06-24 ナチュラルエンド テック カンパニー リミテッド インシュリン様成長因子−１の分泌誘導用薬剤学的組成物および食品組成物
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
EP2763692A2 (en) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
SE9201573D0 (sv) 1992-05-19
US5466670A (en) 1995-11-14
AU4098893A (en) 1993-12-13
DE69331045D1 (de) 2001-12-06
ATE207758T1 (de) 2001-11-15
CA2112358A1 (en) 1993-11-25
EP0613376B1 (en) 2001-10-31
EP0613376A1 (en) 1994-09-07
JPH06509361A (ja) 1994-10-20
DE69331045T2 (de) 2002-03-21
AU669894B2 (en) 1996-06-27
WO1993023071A1 (en) 1993-11-25
NZ252359A (en) 1997-05-26
NO940180D0 (no) 1994-01-18

Similar Documents

Publication Publication Date Title
MX9701916A (es) Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.
ATE207758T1 (de) Verwendung von igf-1
TR200100079T2 (tr) Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE82507T1 (de) Medizinische verwendung.
IT8323559A0 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
MD1558G2 (ro) Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
EP0700681A4 (en) Nutritional transfusion for peripheral vein administration
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
ATE22655T1 (de) Infusionsloesungen zur herztherapie.
CS151887A2 (en) Method of sound, physiologically normal farming animal's mamma parenchyma's growth increase
CA2252560A1 (en) Treatment of partial growth hormone insensitivity syndrome
NO20000007L (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
CA2405265A1 (en) Method of preventing or treating diabetes
EP0321094A3 (en) Treatment of factor viii inhibitors
李祖谟 235 CASES OF FROZEN SHOULDERTREATED BY MANIPULATIONANDMASSAGE
AU5199286A (en) New use of 1,4-dihydropyridine derivatives
Gemsenjäger et al. Contralateral Papillary Thyroid Cancer—High Incidence in Therapeutic Completion Thyroidectomy
Holst et al. Diurnal profile of pancreatic polypeptide and gut glucagon in human morbid obesity
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DK105791D0 (da) Broed-erstattende fiberholdigt produkt med blodsukker saenkende og insulin besparende virkning. udelukkende tillavet af naturlige foedevare-ingredienser
RU92008227A (ru) Способ улучшения настроения и самочувствия